A new study led by Stephen D. Nimer, M.D.,director of Sylvester Comprehensive Cancer Center, shows how a key molecule regulates the generation of new blood cells, a process called hematopoiesis that goes awry in cancer. The findings have the potential to lead to new therapeutic strategies targeting the molecule, a regulator of gene activity called TAF1.

Preoperative delay when treating breast cancer confers poorer outcomes, but growth rates and the upstaging likelihoods per delay interval remain unknown. This study evaluated upstaging risk, nodal spread, and tumor growth rates in vivo while awaiting treatment.

Salk Institute Professor Diana Hargreaves was named a 2025 All-Star Translational Award Program grantee by the V Foundation for Cancer Research. The award comes as a recognition of Hargreaves’ exceptional success with her previous V Foundation grant in 2016. For the All-Star project, she will receive $1 million and work with collaborator Gregory Botta, an associate professor at UC San Diego Moores Cancer Center, to improve immunotherapy—a treatment that utilizes the body’s own immune cells to fight cancer—in patients with pancreatic cancer.

The new location of the Josep Carreras Leukaemia Research Institute will be based at Sant Joan de Déu and will focus on research into paediatric leukaemia. This new programme is the result of an agreement between the Institute, the Josep Carreras Foundation, and the Sant Joan de Déu Research Institute, which will enable the development of joint institutional strategies and initiatives, and promote collaborative research in all its phases.